Earnings ·
Entera Bio reports $0.11 Q3 loss and raises cash to $265.9M via $275M private placement
ENTXEntera Bio Ltd.
Entera Bio Ltd. reported a net loss of $15.6 million, or $0.11 per share, for the third quarter ended September 30, 2026, compared to a $3.2 million loss in the prior-year period. The increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants and higher research expenses related to the EB613 Phase 3 program startup. Cash and cash equivalents rose to $265.9 million following a July 2026 oversubscribed private placement that raised approximately $275.0 million in gross proceeds. The company also announced key leadership appointments, including a new Chief Medical Officer and two board members, while advancing clinical preparations for its EB613 osteoporosis study with first site activation expected in late 2026. Entera Bio Ltd. is a clinical-stage biotechnology company focused on developing oral peptide therapies.